- Home
- ACHV vs IKT Comparison
ACHV vs IKT Comparison
Compare ACHV & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHV | IKT |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.7M | 201.3M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACHV | IKT |
|---|---|---|
| Price | $4.75 | $2.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $15.50 | $6.00 |
| AVG Volume (30 Days) | 464.6K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.33 | ★ 67.51 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.84 | $1.33 |
| 52 Week High | $6.03 | $2.58 |
Technical Indicators
Market Signals| Indicator | ACHV | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 67.70 |
| Support Level | $4.65 | $1.45 |
| Resistance Level | $5.30 | $2.11 |
| Average True Range (ATR) | 0.24 | 0.14 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 99.37 | 75.36 |
Price Performance
Historical ComparisonAbout ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.